Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer — Stella

Recruiting

Back to Prostate Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

Peking University Cancer Hospital, Beijing, Beijing Municipality

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Sinotau Pharmaceutical Group

Enrollment target

~32 participants

Started

September 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Sex

Male only

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov